Ashvind Prabahran

Ashvind Prabahran

Auto-generated profile, based on publicly available information

Ashvind Prabahran

Department Clinical Haematology Austin Hospital Heidelberg Victoria Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
APAshvind Prabahran
Ashvind Prabahran
RKRachel Koldej
Rachel Koldej
LCLynette Chee
Lynette Chee
DRDavid S. Ritchie
David S. Ritchie
Poor graft function (PGF), defined by the presence of multilineage cytopenias in the presence of 100% donor chimerism, is a serious complication of allogeneic stem cell transplant (alloSCT). Inducers or potentiators of alloimmunity such as cytomegalovirus reactivation and graft-versus-host disease are associated with the development of PGF, however, more clinical studies are required to establish further risk factors and describe outcomes of PGF. The pathophysiology of PGF can be conceptualized as dysfunction related to the number or productivity of the stem cell compartment, defects in bone marrow microenvironment components such as mesenchymal stromal cells and endothelial cells, or immunological suppression of post-alloSCT hematopoiesis. Treatment strategies focused on improving stem cell number and function and microenvironment support of hematopoiesis have been attempted with variable success. There has been limited use of immune manipulation as a therapeutic strategy, but emerging therapies hold promise. This review details the current understanding of the causes of PGF and methods of treatment to provide a framework for clinicians managing this complex problem.

31 January 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
APAshvind Prabahran
Ashvind Prabahran
RKRachel Koldej
Rachel Koldej
LCLynette Chee
Lynette Chee
EWEric Wong
Eric Wong
DRDavid Ritchie
David Ritchie
Poor Graft Function (PGF) is defined by multi-lineage cytopenias with complete donor chimerism post allogeneic transplantation, Risk factors for and subsequent mortality from PGF were assessed in our transplant cohort. Non-sibling donor [OR 1.97; 95% CI 1.02–3.70], ICU admission [OR 5.28; 95% CI 2.29–11.88] or blood culture positivity within the first 30 days [OR 1.67; 95% CI 1.07–2.62], grade III–IV acute graft vs host disease (GVHD) [OR 4.082; 95% CI 2.31–7.16] and CMV viremia [OR 2.43; 95% CI 1.53–3.88] and were significantly associated with development of PGF. PGF patients without count recovery had a 2 year OS of 6%. Severe GVHD, thrombocytopenia and anemia portended inferior survival and were used to develop a prognostic score for mortality from PGF. This analysis identifies risk factors predictive of PGF and poor survival in those without recovery.

1 May 2018 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
APAshvind Prabahran
Ashvind Prabahran
MTMark Tacey
Mark Tacey
SFShaun Fleming
Shaun Fleming
AWAndrew Wei
Andrew Wei
CTCourtney Tate
Courtney Tate
LCLynette Chee
Lynette Chee

17 July 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
APAshvind Prabahran
Ashvind Prabahran
JDJibran Durrani
Jibran Durrani
JSJuan Coelho‐Da Silva
Juan Coelho‐Da Silva
RSRuba Shalhoub
Ruba Shalhoub
JLJennifer Lotter
Jennifer Lotter
EGEmma M. Groarke
Emma M. Groarke

23 July 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
APAshvind Prabahran
Ashvind Prabahran
RKRachel Koldej
Rachel Koldej
LCLynette Chee
Lynette Chee
Jeff SzerJeff Szer
Jeff Szer
DRDavid Ritchie
David Ritchie

29 March 2018 in Blood
Verified
Journal Article
Closed access
APAshvind A. Prabahran
Ashvind A. Prabahran
SJSurender K Juneja
Surender K Juneja